Zimbabwe has declined a major American healthcare agreement worth $367m (272 million pounds) spanning five years due to the United States' demand for sensitive data.
The decision came to light after a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesperson later stated that the US was seeking biological samples for scientific study and commercial gain while refused to share the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more negotiations to find a deal suitable to both sides so the country's critical HIV programme can continue.
Broader Background
This rejection comes after a comparable case in Kenya, where a high court blocked a related deal with the US after concerns were raised about the safety of citizens' medical information.
After resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, without any equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that provided information," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens if a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining systems already established through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to further discussions with our US partners on how future co-operation might be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it recognised the government's concerns, but suggested that talks need to persist given that much of the nation's HIV programmes were funded by external financing.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it commented.
This impasse highlights the complex debate between receiving vital foreign assistance and safeguarding local interests in an increasingly data-driven world.